The objective of this study was to evaluate pharmacodynamical properties of transdermal therapeutic systems (TTS) containing @entity20805 together with synthetic and pH independent polymers, @entity21049 RL 100 and RS 100. Optimum formulation was chosen according to the results of our previous study regarding in vitro dissolution and ex vivo diffusion rate studies through excised @entity1 skin by using Franz Diffusion Cell. Control group, @entity101 ( @entity101 ) and TTS containing @entity20805 @entity101 ( @entity101 ) were assessed for the pharmacodynamic activity of the study. Pharmacodynamic activity of transdermal patches containing @entity20805 was evaluated in @entity35 by the measurement of systolic blood pressure for 24 h with the use of the tail cuff method. Blood pressure, heart rate, body and heart weight, heart and body weight ratio were determined. @entity880 dehydrogenase (LDH), @entity1011 phosphokinase (CPK), @entity2041 ( @entity6172 ), @entity1234 ( @entity1865 ), @entity1589 ( @entity1589 ) and @entity4024 , @entity3529 -ATPase were measured in the serum of @entity35 . Histopathological evaluation of the heart tissue was conducted in order to determine any tissue damage. Blood pressure values of the TTS containing @entity20805 @entity101 were decreased significantly and became almost similar with the blood pressure values of the control group. These results indicated that matrix type transdermal patches prepared with @entity21049 RL 100 and RS 100 polymers containing @entity20805 can be considered as transdermal therapeutic systems for chronical treatment of @entity101 and @entity712 . However, further in vivo pharmacokinetic studies should be performed in order to determine the blood level of the drug.

PHARMACODYNAMICAL EVALUATION OF MATRIX TYPE TRANSDERMAL THERAPEUTIC SYSTEMS CONTAINING XXXX .

@entity1 :: ('9606', 'Species') :: ['human'] @entity20805 :: ('D002216', 'Chemical') :: ['captopril'] @entity4024 :: ('D012964', 'Chemical') :: ['Na+'] @entity101 :: ('MESH:D006973', 'Disease') :: ['HT', 'HT-CAP', 'hypertension group', 'hypertension'] @entity3529 :: ('D011188', 'Chemical') :: ['K(+)'] @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure'] @entity2041 :: ('MESH:D005978', 'Chemical') :: ['glutathione'] @entity6172 :: ('D005978', 'Chemical') :: ['GSH'] @entity1234 :: ('MESH:D008315', 'Chemical') :: ['malondialdehyde'] @entity21049 :: ('MESH:C038300', 'Chemical') :: ['Eudragit'] @entity880 :: ('MESH:D019344', 'Chemical') :: ['Lactate'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity1589 :: ('303413(Tax:10116)', 'Gene') :: ['MPO', 'myeloperoxidase'] @entity1865 :: ('CHEBI:566274', 'Chemical') :: ['MDA']
@entity20805 :: (D002216,Chemical) :: ['CAPTOPRIL']
